NextCure (NASDAQ:NXTC) Major Shareholder Purchases $38,990.00 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc acquired 7,798 shares of the firm’s stock in a transaction dated Monday, July 27th. The stock was purchased at an average cost of $5.00 per share, with a total value of $38,990.00. Following the transaction, the insider owned 383,456 shares in the company, valued at approximately $1,917,280. This trade represents a 2.08% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc bought 6,400 shares of NextCure stock. The stock was purchased at an average price of $4.95 per share, with a total value of $31,680.00.

NextCure Stock Performance

NextCure stock opened at $4.14 on Friday. The stock has a 50-day simple moving average of $3.49 and a 200 day simple moving average of $8.68. The stock has a market capitalization of $14.95 million, a P/E ratio of -0.24 and a beta of 1.42. NextCure, Inc. has a 52 week low of $1.55 and a 52 week high of $15.74.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.10) by $0.23. Research analysts forecast that NextCure, Inc. will post -7.89 earnings per share for the current year.

Hedge Funds Weigh In On NextCure

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of NextCure by 18.6% during the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares during the period. Renaissance Technologies LLC lifted its holdings in NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares during the last quarter. Marshall Wace LLP bought a new stake in NextCure in the 4th quarter valued at $160,000. Millennium Management LLC bought a new stake in NextCure in the 4th quarter valued at $185,000. Finally, Affinity Asset Advisors LLC grew its holdings in NextCure by 28.9% in the 4th quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock valued at $3,509,000 after buying an additional 55,412 shares in the last quarter. Institutional investors and hedge funds own 42.65% of the company’s stock.

Analysts Set New Price Targets

NXTC has been the subject of several research reports. Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of NextCure in a research note on Wednesday, July 15th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, NextCure presently has a consensus rating of “Hold” and an average target price of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.